Novartis AG Thinks Twice About RNAi Development, Slims Down R&D Group In Boston
Novartis isn't the only one hiring, others are hiring too! Check it out! (Isn't it tempting?)
Swiss drug maker Novartis AG said Monday it is cutting back on a research program in Cambridge trying to develop drugs using a gene-silencing technology called RNA interference.
The company has 26 researchers working on RNA medicines and will reduce the team to a small but unspecified number, said Jeff Lockwood, spokesman for the Cambridge-based Novartis Institutes for BioMedical Research, the drug maker’s global research headquarters. Lockwood said he did not know how many researchers, if any, would lose their jobs.
Don't forget, hundreds of biopharma companies are hiring! (We know you can't resist.)
Swiss drug maker Novartis AG said Monday it is cutting back on a research program in Cambridge trying to develop drugs using a gene-silencing technology called RNA interference.
The company has 26 researchers working on RNA medicines and will reduce the team to a small but unspecified number, said Jeff Lockwood, spokesman for the Cambridge-based Novartis Institutes for BioMedical Research, the drug maker’s global research headquarters. Lockwood said he did not know how many researchers, if any, would lose their jobs.
Don't forget, hundreds of biopharma companies are hiring! (We know you can't resist.)